1. Home
  2. SOHU vs PRTA Comparison

SOHU vs PRTA Comparison

Compare SOHU & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sohu.com Limited

SOHU

Sohu.com Limited

HOLD

Current Price

$14.74

Market Cap

391.6M

Sector

Technology

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.78

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOHU
PRTA
Founded
1996
2012
Country
China
Ireland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
391.6M
539.9M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
SOHU
PRTA
Price
$14.74
$10.78
Analyst Decision
Strong Buy
Buy
Analyst Count
2
9
Target Price
$20.00
$19.00
AVG Volume (30 Days)
45.6K
453.1K
Earning Date
05-18-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$814,000.00
Revenue This Year
$1.61
$1,111.38
Revenue Next Year
$3.78
N/A
P/E Ratio
$1.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.85
$4.32
52 Week High
$17.30
$11.69

Technical Indicators

Market Signals
Indicator
SOHU
PRTA
Relative Strength Index (RSI) 34.49 67.58
Support Level $14.22 $9.69
Resistance Level $16.13 $10.90
Average True Range (ATR) 0.55 0.40
MACD -0.06 0.11
Stochastic Oscillator 9.78 99.15

Price Performance

Historical Comparison
SOHU
PRTA

About SOHU Sohu.com Limited

Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: